Close Menu

Trovagene

Trovagene has appointed Paul Billings to its board of directors. Billings is currently chief medical officer at Life Technologies and is a member of Trovagene's scientific advisory board.

Paired Ends: Paul Billings

Premium

Trovagene has appointed Paul Billings to its board of directors. Billings is currently chief medical officer at Life Technologies and is a member of Trovagene's scientific advisory board.

Paul Billings has been appointed to Trovagene's board of directors, the company said this week.

Trovagene this week announced that its CLIA laboratory is now offering a test for the detection of the BRAF V600E mutations in cell-free DNA in urine.

NEW YORK (GenomeWeb News) – Trovagene today announced a clinical collaboration agreement with the University of Southern California for the use of the San Diego-based firm's cell-free DNA assays to genomically characterize metastatic colorectal cancers.

Trovagene is using RainDance Technologies' RainDrop Digital PCR system to develop and eventually run a cell-free transrenal BRAF mutation assay out of Trovagene's CLIA lab, the companies said this week.

NEW YORK (GenomeWeb News) – Molecular diagnostics developer Trovagene today said that it has closed on a registered direct offering of $15 million of its common stock to an institutional investor at $7 per share.

Trovagene's stockholders have approved all six of the nominees for its board of directors, all of whom are current directors, to serve until the 2014 annual stockholder meeting.

NEW YORK (GenomeWeb News) – Cantor Fitzgerald on Monday initiated coverage of molecular diagnostics firm Trovagene with a Buy rating and a $10 price target on the company's stock.

NEW YORK (GenomeWeb News) – Trovagene said in a regulatory filing today that it has entered into a deal with Illumina to evaluate the possible integration of Trovagene's transrenal technology with Illumina's sequencing technology.

Pages

The US Department of Justice has proposed a rule change to enable DNA to be collected from migrants, the Associated Press reports.

Bernard Fisher, a surgeon who changed how breast cancer is treated, has died at 101, the New York Times reports.

Washington Post columnist writes that she is skeptical about DNA-based diets.

In PNAS this week: recurrent inactivation of DEPDC5 in gastrointestinal stromal tumors, taxonomic reliability of GenBank sequences, and more.